Company intelligence / Profile preview

Uro-Research

Ownership: Private
Development stage: Other

Overview

Uro-Research, LLC developed the Tissue Bonding Cystostomy ("TBC"), a novel device intended to improve urinary drainage and reduce infection risk in patients with neurogenic bladder following spinal cord injury. The company has conducted at least one Phase 1 clinical trial but no recent updates are available regarding results or further development. The TBC aims to address limitations of traditional catheterization by reducing bacterial colonization and infection rates. No commercial products or late-stage programs are reported as of January 2025.

Therapeutic areas: Neurology
Modalities: Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Uro-Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uro-Research.

Explore the full profile